The Discounted Cash Flow (DCF) valuation of Tekla Life Sciences Investors (HQL) is 27.34 USD. With the latest stock price at 16.84 USD, the upside of Tekla Life Sciences Investors based on DCF is 62.3%.
Based on the latest price of 16.84 USD and our DCF valuation, Tekla Life Sciences Investors (HQL) is a buy. buying HQL stocks now will result in a potential gain of 62.3%.
| Range | Selected | |
| WACC / Discount Rate | 5.7% - 6.6% | 6.2% |
| Long-term Growth Rate | 0.0% - 1.0% | 0.5% |
| Fair Price | 23.78 - 32.32 | 27.34 |
| Upside | 41.2% - 91.9% | 62.3% |